Clinical Trial

Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer

Study acronym: OPTIMAL-BC
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of oral paclitaxel plus fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in the neoadjuvant treatment of HER2+ breast cancer patients.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-29; most recent amendment 2026-04-27.
Status change: Not Yet Recruiting → Recruiting 2025-08-19
Trial Details
NCT Number NCT07095023
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Peking University Cancer Hospital & Institute, Peking University Shenzhen Hospital, Hainan People's Hospital, The Affiliated Hospital Of Guizhou Medical University, Nanfang Hospital, Southern Medical University, Guangdong Women and Children Hospital, Affiliated Cancer Hospital of Shantou University Medical College, First Affiliated Hospital of Wenzhou Medical University, Cancer Hospital of Guangxi Medical University
Conditions Breast Cancers
Enrollment 112 participants
Start Date 2025-08-15
Primary Completion 2026-12-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-04-29